Literature DB >> 29651121

Classification of myositis.

Ingrid E Lundberg1,2, Marianne de Visser3, Victoria P Werth4.   

Abstract

The idiopathic inflammatory myopathies (IIMs; also known as myositis) are a heterogeneous group of disorders in which a common feature is chronic inflammation of skeletal muscle, leading to muscle weakness. Other organs are frequently affected in IIMs, such as the skin, joints, lungs, gastrointestinal tract and heart, contributing to morbidity and mortality. Currently, IIMs are most often subclassified into polymyositis, dermatomyositis and inclusion body myositis, but this subclassification has limitations as these subgroups often have overlapping clinical and histopathological features, and outcomes vary within the subgroups; additionally, subgroups without considerable myopathy are not included. A new way of subgrouping patients could be on the basis of the presence of myositis-specific autoantibodies. These autoantibodies are associated with distinct clinical features and, moreover, can help to identify subsets of IIMs in which extramuscular symptoms, such as skin manifestations, arthritis or interstitial lung disease, might be the presenting or predominant feature when muscle symptoms are mild or absent. The recognition that subphenotypes with single-organ involvement other than muscles exist is important for identifying patients with early disease, for clinical care demanding team management and in designing clinical studies to improve our understanding of this heterogeneous disease to develop new therapies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29651121     DOI: 10.1038/nrrheum.2018.41

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  63 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands.

Authors:  Jessica E Hoogendijk; Anthony A Amato; Bryan R Lecky; Ernest H Choy; Ingrid E Lundberg; Michael R Rose; Jiri Vencovsky; Marianne de Visser; Richard A Hughes
Journal:  Neuromuscul Disord       Date:  2004-05       Impact factor: 4.296

Review 3.  Polymyositis, dermatomyositis and inclusion-body myositis.

Authors:  M C Dalakas
Journal:  N Engl J Med       Date:  1991-11-21       Impact factor: 91.245

4.  Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features.

Authors:  Stefen Brady; Waney Squier; David Hilton-Jones
Journal:  J Neurol Neurosurg Psychiatry       Date:  2013-07-16       Impact factor: 10.154

5.  Perifascicular necrosis in anti-synthetase syndrome beyond anti-Jo-1.

Authors:  Akinori Uruha; Shigeaki Suzuki; Norihiro Suzuki; Ichizo Nishino
Journal:  Brain       Date:  2016-06-05       Impact factor: 13.501

Review 6.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

Review 7.  A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.

Authors:  Pedram Gerami; Jennifer M Schope; Lauren McDonald; Hobart W Walling; Richard D Sontheimer
Journal:  J Am Acad Dermatol       Date:  2006-01-23       Impact factor: 11.527

8.  Comparison of the reliability and validity of outcome instruments for cutaneous dermatomyositis.

Authors:  R Q Klein; C A Bangert; M Costner; M K Connolly; A Tanikawa; J Okawa; M Rose; S S Fakharzadeh; D Fiorentino; L A Lee; R D Sontheimer; L Taylor; A B Troxel; V P Werth
Journal:  Br J Dermatol       Date:  2008-07-04       Impact factor: 9.302

9.  Myofiber HLA-DR expression is a distinctive biomarker for antisynthetase-associated myopathy.

Authors:  Jessie Aouizerate; Marie De Antonio; Guillaume Bassez; Romain K Gherardi; Francis Berenbaum; Loïc Guillevin; Alice Berezne; Dominique Valeyre; Thierry Maisonobe; Odile Dubourg; Anne Cosnes; Olivier Benveniste; François Jérôme Authier
Journal:  Acta Neuropathol Commun       Date:  2014-10-23       Impact factor: 7.801

Review 10.  Ongoing developments in sporadic inclusion body myositis.

Authors:  Pedro M Machado; Mhoriam Ahmed; Stefen Brady; Qiang Gang; Estelle Healy; Jasper M Morrow; Amanda C Wallace; Liz Dewar; Gita Ramdharry; Matthew Parton; Janice L Holton; Henry Houlden; Linda Greensmith; Michael G Hanna
Journal:  Curr Rheumatol Rep       Date:  2014-12       Impact factor: 4.592

View more
  56 in total

Review 1.  [What the rheumatologist can learn from the dermatologist-or: nobody can separate good friends : Interfaces of both domains].

Authors:  K Schäkel; A Schirra
Journal:  Z Rheumatol       Date:  2018-08       Impact factor: 1.372

2.  Slicing and dicing myositis for cures and prevention.

Authors:  Frederick W Miller
Journal:  Nat Rev Rheumatol       Date:  2021-05       Impact factor: 20.543

Review 3.  Interstitial Pneumonia With Autoimmune Features: An Emerging Challenge at the Intersection of Rheumatology and Pulmonology.

Authors:  Erin M Wilfong; Robert J Lentz; Adam Guttentag; James J Tolle; Joyce E Johnson; Jonathan A Kropski; Peggy L Kendall; Timothy S Blackwell; Leslie J Crofford
Journal:  Arthritis Rheumatol       Date:  2018-10-27       Impact factor: 10.995

Review 4.  Arthritis in Idiopathic Inflammatory Myopathies.

Authors:  Martin Klein; Heřman Mann; Jiří Vencovský
Journal:  Curr Rheumatol Rep       Date:  2019-12-07       Impact factor: 4.592

5.  Comparison of the 2017 EULAR/ACR criteria with Bohan and Peter criteria for the classification of idiopathic inflammatory myopathies.

Authors:  Benzeeta Pinto; Ramya Janardana; Raghunanadan Nadig; Anita Mahadevan; Anusha S Bhatt; John Michael Raj; Vineeta Shobha
Journal:  Clin Rheumatol       Date:  2019-03-22       Impact factor: 2.980

6.  Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort.

Authors:  Aswin M Nair; John Mathew; Ruchika Goel; Pramod Chebbi; Ashish Jacob Mathew; G Arvind; Bijesh Yadav; Grace Rebekah; John A J Prakash; Debashish Danda
Journal:  Clin Rheumatol       Date:  2021-01-27       Impact factor: 2.980

Review 7.  Polymyositis with mitochondrial pathology or atypical form of sporadic inclusion body myositis: case series and review of the literature.

Authors:  George K Papadimas; Charalampos Kokkinis; Sophia Xirou; Margarita Chrysanthou; Evangelia Kararizou; Constantinos Papadopoulos
Journal:  Rheumatol Int       Date:  2019-05-04       Impact factor: 2.631

8.  The significance of myositis autoantibodies in idiopathic inflammatory myopathy concomitant with interstitial lung disease.

Authors:  Wen-Chih Lin; Po-Yu Lin; Hung-Ling Huang; Meng-Yu Weng; Yuan-Ting Sun
Journal:  Neurol Sci       Date:  2020-11-19       Impact factor: 3.307

9.  Generation and validation of recombinant antibodies to study human aminoacyl-tRNA synthetases.

Authors:  Charlotta Preger; Edvard Wigren; Elena Ossipova; Carolyn Marks; Johan Lengqvist; Camilla Hofström; Oskar Andersson; Per-Johan Jakobsson; Susanne Gräslund; Helena Persson
Journal:  J Biol Chem       Date:  2020-08-14       Impact factor: 5.157

10.  Advances in Cutaneous Lupus Erythematosus and Dermatomyositis: A Report from the 4th International Conference on Cutaneous Lupus Erythematosus-An Ongoing Need for International Consensus and Collaborations.

Authors:  Josef Symon S Concha; Aikaterini Patsatsi; Ann Marshak-Rothstein; Ming-Lin Liu; Animesh A Sinha; Lela A Lee; Joseph F Merola; Ali Jabbari; Johann E Gudjonsson; François Chasset; Paul Jarrett; Benjamin Chong; Lisa Arkin; Anthony P Fernandez; Marzia Caproni; Steven A Greenberg; Hee Joo Kim; David R Pearson; Alisa Femia; Ruth Ann Vleugels; David Fiorentino; Manabu Fujimoto; Joerg Wenzel; Victoria P Werth
Journal:  J Invest Dermatol       Date:  2018-09-19       Impact factor: 8.551

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.